Global Medical Tech Becton, Dickinson Expects Lower China Sales, Bioscience And Pharma Market Dynamics To Impact 2025 Organic Revenue Growth

Benzinga11-08

On Thursday, Becton, Dickinson and Company (NYSE:BDX) reported fourth-quarter sales of $5.44 billion, up 6.9% year over year (+7.4% currency-neutral and 6.2% organic), beating the consensus of $5.38 billion.

“In FY24, our team advanced our strategy, continuing to shift our portfolio into higher-growth areas through new innovations and the acquisition of Edwards Lifesciences’ Critical Care product group, while leveraging our BD Excellence system to exceed our margin expansion, earnings and cash flow goals,” said Tom Polen, chairman, CEO and president of BD.

“Our growth strategy remains focused on delivering solutions for our customers that leverage significant shifts in technology, like biologics, AI and automation, that are revolutionizing patient care.”

BD Medical segment sales increased to $2.84 billion, up 11.1%. Medication Management Solutions led organic revenue growth of 8.6%.

BD Life Sciences sales were almost flat to $1.34 billion, up 0.7% (+1.4% organic), and BD Interventional sales were up 4.7% (+6.6%) to $1.26 billion.

The MedTech player reported adjusted EPS of $3.81, up 11.4%, beating the consensus of $3.77.

Dividend: BD declared a quarterly dividend of $1.04 per share, an increase of 9.5% from the previous quarter. The dividend will be payable on December 31 to holders of record on December 9.

Guidance: BD sees fiscal year 2025 sales of $21.9 billion-$22.1 billion compared to a consensus of $21.75 billion.

The company forecasts an adjusted EPS of $14.25-$14.60 versus the consensus of $14.34.

The company expects revenue growth of 8.9%-9.4% and currency-neutral adjusted revenue growth of 8.8%-9.3%, including the newly acquired Advanced Patient Monitoring business.

The company’s organic revenue growth guidance of 4.0%-4.5% includes absorbing an impact of about 125 basis points from an expected decline in revenues in China and Bioscience and Pharma market dynamics.

Price Action: BDX stock is down 3.96% at $230.55 at the last check on Thursday.

Read Next:

  • Security Company GEO’s Q3 Miss: Lower ISAP Participants Offset By Strategic Contracts
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment